H-Index
10
Scimago Lab
powered by Scopus
eISSN: 2325-4416

Logo



Can calcium dobesilate be used safely for peripheral microvasculopathies that require neoangiogenesis?

Sinan Demirtas, Ahmet Caliskan, Orkut Guclu, Suleyman Yazici, Oguz Karahan, Celal Yavuz, Binali Mavitas

(Diyarbakir, Turkey)

Med Sci Monit Basic Res 2013; 19:253-257

DOI: 10.12659/MSMBR.889427

Published: 2013-09-27


Background: Calcium dobesilate (CaD) is a member of the synthetic veno-active drug family. Only a small number of reports are available that describe the micro-angiogenic effects of CaD in the current literature.
Material and Methods: The antiangiogenic potential of CaD was compared with bevacizumab (Bb), which is a potent angiogenesis inhibitor, in a chick chorioallantoic membrane model. Four different concentrations (10–7, 10–6, 10–5, and 10–4 M) of drug pellet were prepared for each drug. Changes in vessel formation were scored and compared for each drug according to the previous literature.
Results: The antiangiogenic behavior of CaD was lower than Bb, despite the significant dose-dependent manner of escalation. The anti-angiogenic scores of CaD were determined as 0.20, 0.47, 0.66, 1.0 in 10–7, 10–6, 10–5, and 10–4 M concentrations, respectively (average score >0.5 was significant).
Conclusions: According to the data obtained, this agent should be used carefully for cases in which angiogenesis plays an important role in healing.

Keywords: Neovascularization, Pathologic - drug therapy, Chick Embryo, Microvessels - pathology, Calcium Dobesilate - therapeutic use, Animals, Antibodies, Monoclonal, Humanized - therapeutic use, Angiogenesis Inhibitors - pharmacology, Peripheral Vascular Diseases - pathology



Back